Sugi Predict
/ Targets
/ WRN
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to WRN by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3) |
PHASE3 | COMPLETED |
| Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency |
PHASE2/PHASE3 | RECRUITING |
| ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients |
PHASE3 | COMPLETED |
| Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients |
PHASE3 | COMPLETED |
| Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin |
PHASE2 | COMPLETED |
| Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA) |
PHASE1/PHASE2 | COMPLETED |
| Reverse Transcriptase Inhibitors in AGS |
PHASE2 | COMPLETED |
| A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies |
PHASE1/PHASE2 | RECRUITING |
| Effects of Vitamin B3 in Patients With Ataxia Telangiectasia |
PHASE2 | COMPLETED |
| Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment |
PHASE2 | ACTIVE_NOT_RECRUITING |
| EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors |
PHASE1/PHASE2 | RECRUITING |
| Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) |
PHASE2 | COMPLETED |
| Phase II ABT-888 With Cyclophosphamide |
PHASE2 | COMPLETED |
| A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors |
PHASE1 | COMPLETED |
| Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors |
PHASE1 | COMPLETED |
| Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas |
PHASE1 | COMPLETED |
| Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency. |
PHASE1 | ACTIVE_NOT_RECRUITING |
| Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer |
PHASE1 | COMPLETED |
| A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors |
PHASE1 | RECRUITING |
| Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors |
PHASE1 | ACTIVE_NOT_RECRUITING |
| ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems |
PHASE1 | WITHDRAWN |
| A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors |
PHASE1 | COMPLETED |
| Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors |
PHASE1 | COMPLETED |
| Efficacy and Adverse Effects of Olaparib in Ovarian Cancer. |
nan | UNKNOWN |
| A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients |
nan | COMPLETED |
| Application of Genetic Polymorphisms of DNA Repair in The Prediction of Prostate Cancer Susceptibility and Its Clinical Outcome |
nan | UNKNOWN |
| Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer |
nan | UNKNOWN |
| Biological Aging Hallmarks-Guided Integrative TCM and Conventional Medicine in Post-Treatment Unexplained Female Infertility |
nan | RECRUITING |
| Efficacy and Adverse Effects of Niraparib in Ovarian Cancer. |
nan | UNKNOWN |
Related proteins — ESM-2 sequence neighbours (a WRN binder may also engage these)